In this issue of The Journal of the American Medical Directors Association (JAMDA), Voelker and colleagues present the results of a systematic review and meta-analysis measuring the reliability and concurrent validity of the SARC-F.1 The study reports data gathered from 29 articles and more than 20,000 participants. Overall, the SARC-F shows relatively good inter-rater and test-retest reliability. However, the authors conclude that despite its high specificity, the low to moderate sensitivity of the SARC-F makes it nonoptimal for the screening of sarcopenia. Moreover, Voelker and colleagues tend to discourage the use of the SARC-F, suggesting the direct application of the diagnostic criteria for sarcopenia without prior screening.
Cesari, M., Marzetti, E., Calvani, R., Sarcopenia and SARC-F: “Perfect is the Enemy of Good”, <<JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION>>, 2021; 22 (9): 1862-1863. [doi:10.1016/j.jamda.2021.07.030] [http://hdl.handle.net/10807/200986]
Sarcopenia and SARC-F: “Perfect is the Enemy of Good”
Marzetti, Emanuele;Calvani, Riccardo
2021
Abstract
In this issue of The Journal of the American Medical Directors Association (JAMDA), Voelker and colleagues present the results of a systematic review and meta-analysis measuring the reliability and concurrent validity of the SARC-F.1 The study reports data gathered from 29 articles and more than 20,000 participants. Overall, the SARC-F shows relatively good inter-rater and test-retest reliability. However, the authors conclude that despite its high specificity, the low to moderate sensitivity of the SARC-F makes it nonoptimal for the screening of sarcopenia. Moreover, Voelker and colleagues tend to discourage the use of the SARC-F, suggesting the direct application of the diagnostic criteria for sarcopenia without prior screening.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.